PHCR.F Stock Overview
Provides specialty diagnostic services to consumer and practitioners in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Healius Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.97 |
| 52 Week High | AU$0.97 |
| 52 Week Low | AU$0.97 |
| Beta | 0.74 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -67.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHCR.F | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0% | 1.0% | 0.3% |
| 1Y | n/a | 2.9% | 31.1% |
Return vs Industry: Insufficient data to determine how PHCR.F performed against the US Healthcare industry.
Return vs Market: Insufficient data to determine how PHCR.F performed against the US Market.
Price Volatility
| PHCR.F volatility | |
|---|---|
| PHCR.F Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 7.1% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PHCR.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine PHCR.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 6,994 | Paul Anderson | www.healius.com.au |
Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services.
Healius Limited Fundamentals Summary
| PHCR.F fundamental statistics | |
|---|---|
| Market cap | US$620.46m |
| Earnings (TTM) | -US$414.85m |
| Revenue (TTM) | US$1.14b |
0.6x
P/S Ratio-1.5x
P/E RatioIs PHCR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHCR.F income statement (TTM) | |
|---|---|
| Revenue | AU$1.75b |
| Cost of Revenue | AU$1.21b |
| Gross Profit | AU$541.20m |
| Other Expenses | AU$1.18b |
| Earnings | -AU$636.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.88 |
| Gross Margin | 30.99% |
| Net Profit Margin | -36.42% |
| Debt/Equity Ratio | 40.4% |
How did PHCR.F perform over the long term?
See historical performance and comparison